Compare · AKBA vs ARDX
AKBA vs ARDX
Side-by-side comparison of Akebia Therapeutics Inc. (AKBA) and Ardelyx Inc. (ARDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKBA and ARDX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ARDX is the larger of the two at $1.28B, about 3.6x AKBA ($359.5M).
- Over the past year, AKBA is down 65.3% and ARDX is up 18.0% - ARDX leads by 83.3 points.
- AKBA has been more active in the news (11 items in the past 4 weeks vs 3 for ARDX).
- ARDX has more recent analyst coverage (24 ratings vs 11 for AKBA).
- Company
- Akebia Therapeutics Inc.
- Ardelyx Inc.
- Price
- -
- -
- Market cap
- $359.5M
- $1.28B
- 1M return
- +36.46%
- -8.29%
- 1Y return
- -65.28%
- +18.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2014
- News (4w)
- 11
- 3
- Recent ratings
- 11
- 24
Akebia Therapeutics Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Ardelyx Inc.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Latest AKBA
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SVP, CFO, CBO & Treasurer Ostrowski Erik sold $62,181 worth of shares (56,019 units at $1.11), decreasing direct ownership by 8% to 616,616 units (SEC Form 4) to satisfy withholding tax
- Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
- Director Wolf Myles was granted 35,700 shares, increasing direct ownership by 27% to 169,081 units (SEC Form 4)
- Director Smith Cynthia was granted 35,700 shares, increasing direct ownership by 22% to 196,633 units (SEC Form 4)
- Director Rogers Michael W was granted 35,700 shares, increasing direct ownership by 22% to 197,429 units (SEC Form 4)
- Director Frieson Ron was granted 35,700 shares, increasing direct ownership by 28% to 165,200 units (SEC Form 4)
- Akebia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 33% to 145,100 units (SEC Form 4)
Latest ARDX
- President & CEO Raab Michael exercised 20,834 shares at a strike of $0.99 and sold $210,923 worth of shares (41,668 units at $5.06) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,678,366 units (SEC Form 4)
- Ardelyx Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Chief Patient Officer Williams Laura A exercised 31,000 shares at a strike of $0.99 and sold $490,487 worth of shares (81,898 units at $5.99) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 378,195 units (SEC Form 4)
- Director Parsey Merdad was granted 26,455 shares, increasing direct ownership by 46% to 83,746 units (SEC Form 4)
- Director Rodgers Richard J was granted 26,455 shares, increasing direct ownership by 6% to 439,998 units (SEC Form 4)
- Director Mott David M was granted 46,737 shares, increasing direct ownership by 1% to 3,349,655 units (SEC Form 4)
- Director Cadoret-Manier Onaiza was granted 26,455 shares, increasing direct ownership by 17% to 178,156 units (SEC Form 4)
- Director Bhanji Muna was granted 26,455 shares, increasing direct ownership by 19% to 163,808 units (SEC Form 4)
- Director Bertrand William C Jr was granted 38,800 shares, increasing direct ownership by 13% to 329,507 units (SEC Form 4)
- Director Bazemore Robert B was granted 26,455 shares, increasing direct ownership by 64% to 68,006 units (SEC Form 4)